STX17: A Potential Drug Target Or Biomarker for Cancer and Other Diseases

Target Name: STX17

NCBI ID: G55014

STX17

STX17: A Potential Drug Target Or Biomarker for Cancer and Other Diseases

STX17 (MGC102796) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the STX17 family, which is characterized by the presence of a unique C-terminal domain that is composed of a series of conserved amino acids.

One of the unique features of STX17 is its ability to interact with other proteins, particularly those that are involved in the development and progression of diseases such as cancer. This interaction has led some researchers to consider STX17 as a potential drug target or biomarker for a variety of diseases.

STX17 has been shown to play a role in a number of important biological processes in the body, including the regulation of cell growth, differentiation, and survival. It has also been shown to be involved in the development and progression of a variety of diseases, including cancer.

One of the ways that STX17 is thought to contribute to the development of cancer is by promoting the growth and survival of cancer cells. This is accomplished through the regulation of various cellular processes, including cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

In addition to its role in cancer development, STX17 is also thought to be involved in the regulation of a variety of other cellular processes that are important for maintaining tissue health and function. This includes the regulation of cell signaling pathways, the development and maintenance of tissues and organs, and the regulation of inflammation.

As a potential drug target or biomarker, STX17 has the potential to be used for a variety of diseases, including cancer. By interacting with other proteins that are involved in the development and progression of these diseases, STX17 may be able to cause these proteins to behave in unintended ways, leading to the development of new treatments.

In addition to its potential as a drug target or biomarker, STX17 is also of interest as a potential therapeutic agent for a variety of other diseases. For example, because STX17 is involved in the regulation of cellular processes that are important for maintaining tissue health and function, it may be able to be used to treat a variety of diseases that are characterized by the breakdown of tissues or organs.

Overall, STX17 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Syntaxin 17

Functions: SNAREs, soluble N-ethylmaleimide-sensitive factor-attachment protein receptors, are essential proteins for fusion of cellular membranes. SNAREs localized on opposing membranes assemble to form a trans-SNARE complex, an extended, parallel four alpha-helical bundle that drives membrane fusion (PubMed:23217709, PubMed:25686604, PubMed:28306502). STX17 is a SNARE of the autophagosome involved in autophagy through the direct control of autophagosome membrane fusion with the lysosome membrane (PubMed:23217709, PubMed:25686604, PubMed:28306502, PubMed:28504273). May also play a role in the early secretory pathway where it may maintain the architecture of the endoplasmic reticulum-Golgi intermediate compartment/ERGIC and Golgi and/or regulate transport between the endoplasmic reticulum, the ERGIC and the Golgi (PubMed:21545355)

The "STX17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STX17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets